UY35548A - Péptidos terapéuticos para el tratamiento de trastornos metabólicos. - Google Patents
Péptidos terapéuticos para el tratamiento de trastornos metabólicos.Info
- Publication number
- UY35548A UY35548A UY0001035548A UY35548A UY35548A UY 35548 A UY35548 A UY 35548A UY 0001035548 A UY0001035548 A UY 0001035548A UY 35548 A UY35548 A UY 35548A UY 35548 A UY35548 A UY 35548A
- Authority
- UY
- Uruguay
- Prior art keywords
- treatment
- metabolic disorders
- therapeutic peptides
- pyy
- novel
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 101000585528 Homo sapiens Peptide YY Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818624P | 2013-05-02 | 2013-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35548A true UY35548A (es) | 2014-11-28 |
Family
ID=50842285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035548A UY35548A (es) | 2013-05-02 | 2014-04-30 | Péptidos terapéuticos para el tratamiento de trastornos metabólicos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20160108098A1 (de) |
| EP (1) | EP2992008B1 (de) |
| JP (1) | JP2016519130A (de) |
| KR (1) | KR20160003848A (de) |
| CN (1) | CN105263957A (de) |
| AR (1) | AR096162A1 (de) |
| AU (1) | AU2014261111B2 (de) |
| BR (1) | BR112015027528B1 (de) |
| CA (1) | CA2909045C (de) |
| CL (1) | CL2015003199A1 (de) |
| EA (1) | EA201591839A1 (de) |
| ES (1) | ES2732291T3 (de) |
| HK (1) | HK1214829A1 (de) |
| MX (1) | MX2015015249A (de) |
| PE (1) | PE20151808A1 (de) |
| RU (1) | RU2015144632A (de) |
| SG (1) | SG11201508469YA (de) |
| TW (1) | TW201534616A (de) |
| UY (1) | UY35548A (de) |
| WO (1) | WO2014178018A1 (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
| EP4324475A1 (de) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Zusammensetzungen von glp-1-peptiden und herstellung davon |
| SG11201508469YA (en) * | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| KR20210086717A (ko) | 2013-05-02 | 2021-07-08 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| US10246497B2 (en) | 2013-11-15 | 2019-04-02 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー／エス | ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６） |
| WO2016124687A1 (en) * | 2015-02-04 | 2016-08-11 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| CA2988500A1 (en) | 2015-06-12 | 2016-12-15 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MX2018008019A (es) | 2015-12-28 | 2018-11-09 | Idemitsu Kosan Co | Etiqueta de peptido y proteina etiquetada que incluye la misma. |
| JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| JP2020510028A (ja) | 2017-03-08 | 2020-04-02 | インターシア セラピューティクス，インコーポレイティド | 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法 |
| WO2019149880A1 (en) | 2018-02-02 | 2019-08-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| US11780900B2 (en) | 2018-04-25 | 2023-10-10 | Janssen Sciences Ireland Unlimited Company | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
| TW202535916A (zh) * | 2018-11-01 | 2025-09-16 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
| CA3163507A1 (en) * | 2019-12-04 | 2021-06-10 | The Scripps Research Institute | Peptide conjugates and methods of use |
| KR20230039601A (ko) | 2020-04-17 | 2023-03-21 | 아이투오 테라퓨틱스, 인코포레이티드 | 장기간 작용하는 펩티드 티로신 티로신(pyy) 유사체 및 사용 방법 |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| IL309067A (en) | 2021-06-09 | 2024-02-01 | Scripps Research Inst | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
| CN115960258B (zh) * | 2022-09-30 | 2024-01-12 | 广西医科大学附属肿瘤医院 | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 |
| WO2025217640A1 (en) * | 2024-04-12 | 2025-10-16 | Eli Lilly And Company | Compositions and methods for treating metabolic diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| DE69739172D1 (de) | 1996-08-08 | 2009-01-29 | Amylin Pharmaceuticals Inc | Regulation gastrointestinaler beweglichkeit |
| DK1019077T4 (da) | 1997-08-08 | 2011-03-07 | Amylin Pharmaceuticals Inc | Hidtil ukendte exendinagonistforbindelser |
| US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| JP2001523688A (ja) | 1997-11-14 | 2001-11-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規エキセンジン・アゴニスト化合物 |
| JP2003522721A (ja) | 1997-11-14 | 2003-07-29 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規なエキセンジンアゴニスト化合物 |
| ATE366115T1 (de) | 1998-02-13 | 2007-07-15 | Amylin Pharmaceuticals Inc | Inotropische und diuretische effekte von exendin und glp-1 |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| DE60140625D1 (de) | 2000-08-15 | 2010-01-07 | Univ Illinois | Verfahren zur herstellung von mikropartikeln |
| PL205971B1 (pl) * | 2001-09-24 | 2010-06-30 | Imp Innovations Ltd | Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości |
| JP5638177B2 (ja) * | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
| AU2005289710A1 (en) * | 2004-09-24 | 2006-04-06 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
| EP3000826A1 (de) * | 2004-12-13 | 2016-03-30 | Amylin Pharmaceuticals, LLC | Motive der bauchspeicheldrüsen-polypeptid familie, polypeptide und methoden unter verwendung derselben |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| AU2007230887A1 (en) * | 2006-03-23 | 2007-10-04 | Amylin Pharmaceuticals, Inc. | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases |
| SG10201406063XA (en) | 2009-09-30 | 2014-11-27 | Glaxo Group Ltd | Drug fusions and conjugates with extended half life |
| WO2011050008A2 (en) | 2009-10-19 | 2011-04-28 | Amylin Pharmaceuticals, Inc. | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
| GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| WO2012006566A2 (en) * | 2010-07-09 | 2012-01-12 | Amylin Pharmaceuticals, Inc. | Microcrystalline y receptor agonists |
| GB201101459D0 (en) * | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| SG11201508469YA (en) * | 2013-05-02 | 2015-11-27 | Glaxosmithkline Ip Dev Ltd | Therapeutic peptides |
| US10246497B2 (en) * | 2013-11-15 | 2019-04-02 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
-
2014
- 2014-04-30 SG SG11201508469YA patent/SG11201508469YA/en unknown
- 2014-04-30 MX MX2015015249A patent/MX2015015249A/es unknown
- 2014-04-30 EA EA201591839A patent/EA201591839A1/ru unknown
- 2014-04-30 ES ES14727241T patent/ES2732291T3/es active Active
- 2014-04-30 EP EP14727241.3A patent/EP2992008B1/de active Active
- 2014-04-30 AU AU2014261111A patent/AU2014261111B2/en active Active
- 2014-04-30 AR ARP140101793A patent/AR096162A1/es unknown
- 2014-04-30 CN CN201480024836.3A patent/CN105263957A/zh active Pending
- 2014-04-30 US US14/888,085 patent/US20160108098A1/en not_active Abandoned
- 2014-04-30 UY UY0001035548A patent/UY35548A/es not_active Application Discontinuation
- 2014-04-30 PE PE2015002329A patent/PE20151808A1/es not_active Application Discontinuation
- 2014-04-30 TW TW103115659A patent/TW201534616A/zh unknown
- 2014-04-30 US US14/265,831 patent/US9441023B2/en active Active
- 2014-04-30 CA CA2909045A patent/CA2909045C/en active Active
- 2014-04-30 RU RU2015144632A patent/RU2015144632A/ru not_active Application Discontinuation
- 2014-04-30 BR BR112015027528-1A patent/BR112015027528B1/pt active IP Right Grant
- 2014-04-30 JP JP2016511159A patent/JP2016519130A/ja active Pending
- 2014-04-30 HK HK16102709.0A patent/HK1214829A1/zh unknown
- 2014-04-30 WO PCT/IB2014/061123 patent/WO2014178018A1/en not_active Ceased
- 2014-04-30 KR KR1020157034300A patent/KR20160003848A/ko not_active Ceased
-
2015
- 2015-10-30 CL CL2015003199A patent/CL2015003199A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015003199A1 (es) | 2016-05-06 |
| EP2992008A1 (de) | 2016-03-09 |
| TW201534616A (zh) | 2015-09-16 |
| SG11201508469YA (en) | 2015-11-27 |
| JP2016519130A (ja) | 2016-06-30 |
| AU2014261111B2 (en) | 2017-03-16 |
| WO2014178018A1 (en) | 2014-11-06 |
| CA2909045A1 (en) | 2014-11-06 |
| ES2732291T3 (es) | 2019-11-21 |
| US20140329742A1 (en) | 2014-11-06 |
| PE20151808A1 (es) | 2015-12-16 |
| RU2015144632A (ru) | 2017-06-07 |
| CA2909045C (en) | 2022-12-06 |
| EA201591839A1 (ru) | 2016-05-31 |
| EP2992008B1 (de) | 2019-04-10 |
| US9441023B2 (en) | 2016-09-13 |
| KR20160003848A (ko) | 2016-01-11 |
| BR112015027528B1 (pt) | 2023-02-14 |
| AU2014261111A1 (en) | 2015-11-19 |
| CN105263957A (zh) | 2016-01-20 |
| BR112015027528A2 (pt) | 2017-12-05 |
| US20160108098A1 (en) | 2016-04-21 |
| MX2015015249A (es) | 2016-02-09 |
| AR096162A1 (es) | 2015-12-09 |
| HK1214829A1 (zh) | 2016-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015015249A (es) | Peptidos terapeuticos. | |
| CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
| SV2017005594A (es) | Compuestos co-agonistas de glucagon y glp-1 | |
| MX2016004907A (es) | Analogos del glucagon. | |
| MX2018014016A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
| CO7400885A2 (es) | Análogos de glucagón | |
| BR112016022465A2 (pt) | agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4 | |
| CO2018000809A2 (es) | Anticuerpos para cd40 | |
| UY34859A (es) | Análogos peptídicos de la exendina 4. | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| MX2019013123A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| CL2018000597A1 (es) | Métodos para tratar enfermedades inflamatorias | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
| CL2016000190A1 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca. | |
| ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
| ECSP16075416A (es) | Anticuerpos de il-21 | |
| ECSP16012582A (es) | Compuestos heterocíclicos y métodos de uso | |
| BR112018010155A2 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
| MX2017011194A (es) | Anticuerpos, usos y métodos. | |
| UY34575A (es) | Composiciones y métodos para el tratamiento de diabetes y/u obesidad | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| CL2016001786A1 (es) | Regulación del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes. | |
| UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211206 |